Design Concepts of Virus-Like Particle-Based HIV-1 Vaccines

Frontiers in Immunology

Narcís Saubi¹  Joan Joseph-Munné²  Chun-Wei Chen³ 

[1] EAVI2020 European AIDS Vaccine Initiative H2020 Research Programme, London, United Kingdom;Microbiology Department, Hospital Universitari de la Vall d'Hebron, Barcelona, Spain;Microbiology Department, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain;

关键词: HIV-1;    vaccine;    virus-like particles;    broadly neutralizing antibodies;    cytotoxic T- lymphocyte response;   

DOI  :  10.3389/fimmu.2020.573157

来源: DOAJ

【 摘 要 】

Prophylactic vaccines remain the best approach for controlling the human immunodeficiency virus-1 (HIV-1) transmission. Despite the limited efficacy of the RV144 trial in Thailand, there is still no vaccine candidate that has been proven successful. Consequently, great efforts have been made to improve HIV-1 antigens design and discover delivery platforms for optimal immune elicitation. Owing to immunogenic, structural, and functional diversity, virus-like particles (VLPs) could act as efficient vaccine carriers to display HIV-1 immunogens and provide a variety of HIV-1 vaccine development strategies as well as prime-boost regimes. Here, we describe VLP-based HIV-1 vaccine candidates that have been enrolled in HIV-1 clinical trials and summarize current advances and challenges according to preclinical results obtained from five distinct strategies. This mini-review provides multiple perspectives to help in developing new generations of VLP-based HIV-1 vaccine candidates with better capacity to elicit specific anti-HIV immune responses.

【 授权许可】

Unknown